Adult

InScribe Selected to the GSV Cup Elite 200 for Digital Learning Excellence

Retrieved on: 
Wednesday, January 19, 2022 - 8:30pm

DENVER, Jan. 19, 2022 /PRNewswire-PRWeb/ --InScribe Education (InScribe), which delivers game-changing digital community solutions, has been selected to The Elite 200, the acclaimed list of semifinalists in The GSV Cup, the world's largest pitch competition for EdTech startups run by female-led, multi-stage venture capital firm GSV Ventures.

Key Points: 
  • DENVER, Jan. 19, 2022 /PRNewswire-PRWeb/ --InScribe Education (InScribe), which delivers game-changing digital community solutions, has been selected to The Elite 200, the acclaimed list of semifinalists in The GSV Cup, the world's largest pitch competition for EdTech startups run by female-led, multi-stage venture capital firm GSV Ventures.
  • Companies selected to The Elite 200 represent the top pre-seed and seed-stage startups in digital learning across the "Pre-K to Gray" space.
  • InScribe was selected from a global applicant pool of 750+ companies, the largest application pool for the GSV Cup yet.
  • The 2022 Elite 200 continue to break barriers, comprised of an increasingly diverse and global group:
    The GSV Cup is powered by Google Cloud, HubSpot for Startups, HolonIQ, and GSV Ventures.

One of the Best Books on Online Dating In 2022: Come and Get Your Love

Retrieved on: 
Monday, January 17, 2022 - 8:49pm

Come and Get Your Love follows the life of a single woman named Lovely.

Key Points: 
  • Come and Get Your Love follows the life of a single woman named Lovely.
  • New to both the town and the local dating scene, Lovely turns to an online dating app to find a handsome tour guide to show her around.
  • Reviewers adore Come and Get Your Love, stating, "This book definitely gives a realistic view of the current virtual dating scene.
  • Come and Get Your Love is available for purchase on Amazon.com or wherever books are sold.

PJET Introduces Student Housing App As 1st Step In Building Global Online Marketplace

Retrieved on: 
Wednesday, January 19, 2022 - 4:25pm

New student housing projects are dominated by a handful of large investment firms working at large brand name universities that are putting an estimated $16 billion a year into building new student housing.

Key Points: 
  • New student housing projects are dominated by a handful of large investment firms working at large brand name universities that are putting an estimated $16 billion a year into building new student housing.
  • Smaller colleges with names not as recognizable, which is the vast majority of colleges, remain underserved when it comes to student housing.
  • With student housing in critically short supply, SHBO, as essentially an Airbnb for student housing, is a logical starting point.
  • PJETs SHBO APP is not just a point of entry into the student experience providing access to all student spending through a global Amazon-like marketplace by first helping with housing.

Sorrento Announces Completion of Enrollment in US Phase 2 Clinical Trial for COVI-DROPS and Achievement of Interim Analysis Threshold in the UK

Retrieved on: 
Wednesday, January 19, 2022 - 3:35pm

Key secondary endpoints included the proportion of subjects with medically-attended visits or hospitalizations and the change from baseline in the WHO Clinical Progression Scale score.

Key Points: 
  • Key secondary endpoints included the proportion of subjects with medically-attended visits or hospitalizations and the change from baseline in the WHO Clinical Progression Scale score.
  • Additionally, Sorrento is pleased to announce that the UK Phase 2 study ( www.ClinicalTrials.gov NCT04900428) of intranasal COVI-DROPS treatment in COVID-19 outpatients who are asymptomatic or have mild symptoms has reached the interim analysis threshold of 50% enrollment (n=175).
  • We anticipate reporting on the results from both the US trial and the interim analysis of the UK trial in the coming months.
  • RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients.

TopLine Federal Credit Union Sponsors Student-Led Financial Literacy Research

Retrieved on: 
Wednesday, January 19, 2022 - 3:29pm

MAPLE GROVE, Minn., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Twin Cities-based member-owned cooperative TopLine Federal Credit Union partnered with a group of students from Wayzata High School to research youth financial literacy awareness and create tools to help improve it.

Key Points: 
  • MAPLE GROVE, Minn., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Twin Cities-based member-owned cooperative TopLine Federal Credit Union partnered with a group of students from Wayzata High School to research youth financial literacy awareness and create tools to help improve it.
  • They also created a toolkit with digital tools and content to be used on social media sites to educate on the credit union difference and to increase general financial literacy awareness.
  • Our partnership with TopLine Federal Credit Union has provided students with an opportunity to gain both a financial literacy tool kit and to see the inner workings of a credit union.
  • TopLine Federal Credit Union , a Twin Cities-based credit union, is Minnesotas 13th largest, with assets of more than $650 million and serves nearly 46,000 members.

ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vasculitis

Retrieved on: 
Wednesday, January 19, 2022 - 1:30pm

SAN CARLOS, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that TAVNEOS® (avacopan) has been approved within the European Union in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis. This approval follows the U.S. Food and Drug Administration (FDA) approval of TAVNEOS in October 2021. TAVNEOS will receive marketing authorization in all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.

Key Points: 
  • This approval follows the U.S. Food and Drug Administration (FDA) approval of TAVNEOS in October 2021.
  • TAVNEOS will receive marketing authorization in all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.
  • ChemoCentryx is also developing TAVNEOS for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS) and Lupus Nephritis (LN).
  • In the United States, ChemoCentryx markets TAVNEOS (avacopan), the first approved orally-administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis.

American Oncology Network Appoints New Executive Board Member

Retrieved on: 
Wednesday, January 19, 2022 - 12:49pm

He joins current Executive Board members: Stephen Orman, MD, Douglas Heldreth, MD, Vipul Patel, MD and Daniel Spitz, MD.

Key Points: 
  • He joins current Executive Board members: Stephen Orman, MD, Douglas Heldreth, MD, Vipul Patel, MD and Daniel Spitz, MD.
  • He has served multiple terms on the Executive Board of the largest privately held oncology group in the United States and is a former member of their Finance Committee.
  • He is also a board member of the Florida Society of Clinical Oncology (FLASCO) and was the previous Vice President of the Clinical Practice Committee for FLASCO.
  • American Oncology Network, LLC (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success of community oncology.

Vivos Therapeutics Announces 18X Increase in Sleep Apnea Diagnostic Testing By Vivos Dentists Using SleepImage Technology

Retrieved on: 
Wednesday, January 19, 2022 - 12:30pm

HIGHLANDS RANCH, Colo., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring, today announced significant increases across several key metrics for its SleepImage Home Sleep Apnea Tests (HST).

Key Points: 
  • Under the new revenue model with SleepImage, Vivos will lease out the SleepImage ring recorders to Vivos trained dentists at a fixed price that includes a full months worth of diagnostic sleep test reports.
  • Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from mild-to-moderate obstructive sleep apnea (OSA).
  • Vivos also markets and distributes SleepImage diagnostic technology, powered by VivosScore for Home Sleep Testing in adults and children.
  • The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using the Vivos System.

Oncotelic Presenting at BiotechGate Digital Partnering

Retrieved on: 
Wednesday, January 19, 2022 - 2:05pm

AGOURA HILLS, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (Oncotelic or the Company) (OTCQB:OTLC), a leading developer of TGF- therapeutics for oncology and virology, today announced that Dr. Vuong Trieu, Oncotelic Chairman and CEO, will be presenting the Company immunotherapy pipeline at BiotechGate Digital Partnering Feb 7 - 11, 2022.

Key Points: 
  • AGOURA HILLS, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (Oncotelic or the Company) (OTCQB:OTLC), a leading developer of TGF- therapeutics for oncology and virology, today announced that Dr. Vuong Trieu, Oncotelic Chairman and CEO, will be presenting the Company immunotherapy pipeline at BiotechGate Digital Partnering Feb 7 - 11, 2022.
  • Biotechgate Digital Partnering is a premier platform for business licensing and collaboration focusing on companies developing drugs, diagnostics and medical devices.
  • It is an ideal platform to unveil the fully integrated platform of immunotherapies at Oncotelic.
  • OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF- RNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients.

Stem Holdings Granted Adult-Use License for Existing Retail Dispensary in Sacramento, California

Retrieved on: 
Wednesday, January 19, 2022 - 2:00pm

BOCA RATON, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Stem Holdings, Inc. (OTCQX: STMH) (CSE: STEM) (the Company or Stem), a vertically integrated cannabis operator, today announced being granted an adult-use license for its existing Foothills Health & Wellness 4,600 square foot retail storefront in Sacramento, California.

Key Points: 
  • BOCA RATON, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Stem Holdings, Inc. (OTCQX: STMH) (CSE: STEM) (the Company or Stem), a vertically integrated cannabis operator, today announced being granted an adult-use license for its existing Foothills Health & Wellness 4,600 square foot retail storefront in Sacramento, California.
  • In 2021, this location generated approximately $5.5 million in medicinal retail cannabis sales.
  • Steve Hubbard, Interim CEO of Stem, commented, While most of our resources will focus on our vertically integrated operations in Oregon, our Foothills Health & Wellness retail location in Sacramento, California has been our best performing dispensary.
  • Stem holds licenses in the adult use and/or medical cannabis marketplace in the states of Oregon, Nevada, California, and Massachusetts.